Yazar "Erdemci, Burak" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Comparision of Radiochemotherapy Applications that Committing with Two Different Chemotherapies Route in Locally Advanced Lung Cancer
    (Aves, 2020) Ozmen, Hilal Kiziltunc; Sezen, Orhan; Aktan, Meryem; Erdemci, Burak; Alan, Burcu Saglam; Ertekin, Mustafa Vecdi; Ezirmik, Sinan
    Objective: This study investigated pre- and post-treatment tumor and lymph node dimension response rates and differences between side-effect profiles in patients with locally advanced inoperable nonsmall-cell lung cancer (NSCLC) receiving radiotherapy (RT) and concurrent chemotherapy (CT). Materials and Methods: A total of 30 inoperable patients who had not previously received RT and having a mean age of 58.73 +/- 8.65 years with sufficient hematological reserves and normal hepatic and renal functions were included in the study. Those with pleural effusion, supraventricular lymph node metastasis, and N3 lymph node involvement were excluded. Group I (n=15) received a 21-day 75 mg/m(2) cisplatin (D1) and 15 mg/m(2) vinorelbine (D1, D8), whereas Group II (n=15) received 45 mg/m(2) paclitaxel and AUC2 carboplatin weekly. RT was administered using a linear accelerator device with the 3D conformal RT technique at 6-18 MV energy with a 1.8-2 Gy fraction for 6-7 weeks. Results: Patients were randomized into Group I receiving RT and concurrent cisplatin-vinorelbine and Group II receiving weekly paclitaxel-carboplatin CT. Pre- and post-treatment tumor and lymph node dimensions significantly differed in both groups (p<0.001 and p<0.01, respectively). No significant change was observed in post-RT tumor and lymph node dimensions in terms of applied CT regimens (p>0.05). Conclusion: The significant response achieved with concurrent RT and CT in groups I and II in the local advanced stage of NSCLC is important for local tumor control. Responses to treatment in the group of two arms did not differ.
  • Küçük Resim Yok
    Öğe
    The role of melatonin in preventing radiation-induced intestinal injury
    (Imprimatur Publications, 2021) Sezen, Orhan; Erdemci, Burak; Calik, Muhammet; Koc, Mehmet
    Purpose: Despite the therapeutic effects of radiotherapy on tumor cells, it has potential severe adverse effects on the sur- rounding normal tissues. Acute or chronic intestinal adverse effects that are likely to occur in patients undergoing radio- therapy for pelvic and abdominal cancers lead to increased morbidity, significant impairment of the quality of life, and economic losses. Various biological, chemical and pharma- cological agents are being tested to protect from and to treat radiation enteritis. This experimental study aimed to inves- tigate the protective effects of melatonin against radiation induced intestinal injury when administered before radiation exposure in rats. Methods: In the present study, villus height and the number of villi in the ileum and jejunum of rats receiving two dif- ferent doses of intraperitoneal melatonin (5 and 10 mg/kg) prior to a single fraction of radiation given at a dose of 8 Gy to the abdominal region, was evaluated by histopathological examination 3 and 7 days after radiation exposure. Results: At a dose of 5 mg/kg, melatonin was found to be effective in preventing radiation-induced injury to villus height in the jejunum and the number of villi in the ileum and jejunum, and at a dose of 10 mg/kg it was also effective in preventing radiation-induced injury to villus height in the ileum. Conclusions: Melatonin is effective for the prevention of radiation-induced intestinal injury. This outcome can be considered an evidence to test melatonin in clinical trials.